Cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1)

Cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1) is a secreted protein belonging to the CAP (cysteine-rich secretory protein/antigen 5/pathogenesis-related 1) superfamily. It contains several functional domains, including two LCCL domains and V5/Tpx-1 conserved sites. CRISPLD1 is expressed at low baseline levels in the heart and is upregulated during the progression from compensated cardiac hypertrophy to heart failure, implicating it in the regulation of calcium cycling and cardiac contractility[1]. Its protein sequence shows homology to ion channel regulatory toxins, suggesting potential modulatory effects on ion homeostasis. Genetic associations link CRISPLD1 to craniofacial morphogenesis (e.g., risk for nonsyndromic cleft lip/palate), and it may act cooperatively with CRISPLD2 and folate pathway genes[3]. While its specific biochemical and therapeutic functions remain incompletely characterized, it has emerged as a potentially important player in cardiac remodeling and a possible prognostic biomarker in hematologic malignancies such as acute myelocytic leukemia[1][3]. No current drugs are known to directly target CRISPLD1, nor are there established safety concerns related to CRISPLD1 as a therapeutic target.

Other names

CRISP10CRISP-10LCRISP1UNQ342/PRO541CocoaCrispDKFZp762F133trypsin inhibitor Hlcysteine-rich secretory protein 10LCCL domain-containing cysteine-rich secretory protein 1CRLD1_HUMAN